Dublin, Aug. 12, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Asthma: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis" report to their offering. The increasing availability of biologics will drive growth in the asthma market during 2015-24, but prescribing will be restricted to patients with severe persistent uncontrolled asthma. This report addresses the following questions: - Where will the newly approved Nucala and Cinqair be positioned in the treatment algorithm and will they directly compete with Xolair? - What are pulmonologists' views on the late-phase interleukin (IL) inhibitors and how will they differentiate between them? - What clinical endpoints do pulmonologists want to see in trial programs of biologics? - How will the loss of brand exclusivity impact leading inhaled corticosteroid/long-acting beta 2 agonist (ICS/LABA) inhalers? Key Topics Covered: FORECAST: ASTHMA IN THE US, JAPAN, AND 5EU - Advair (fluticasone/salmeterol) - benralizumab - Breo (fluticasone furoate/vilanterol) - Cinqair (reslizumab) - Dulera (mometasone/formoterol) - Flutiform (fluticasone/formoterol) - Nucala (mepolizumab) - Singulair (montelukast) - Spiriva (tiotropium) - Symbicort (budesonide/formoterol) - Xolair (omalizumab) - Primary Research Methodology TREATMENT: ASTHMA - Primary Research Methodology - Disease Definition and Diagnosis - Patient Segmentation - Country Treatment Trees - Current Treatment Options - Prescribing Trends - Impact of Generics - Unmet Needs in Asthma EPIDEMIOLOGY: ASTHMA - Disease Background - Sources and Methodology - Forecast - Epidemiologist Insight - Strengths and Limitations MARKETED DRUGS: ASTHMA - Product profile: Advair - Product profile: Asmanex - Product profile: Breo - Product profile: Cinqair - Product profile: Dulera - Product profile: Flovent - Product profile: Flutiform - Product profile: Nucala - Product profile: Pulmicort - Product profile: Singulair - Product profile: Spiriva - Product profile: Symbicort - Product profile: Xolair PIPELINE: ASTHMA - Clinical Pipeline Overview - Early-Phase Opportunities - Comparator Therapy - Clinical Trial Design - Product profile (late stage): QVM1 - Product profile (late stage): benralizumab - Product profile (late stage): dupilumab - Product profile (late stage): lebrikizumab - Product profile (late stage): masitinib - Product profile (late stage): tralokinumab For more information about this report visit http://www.researchandmarkets.com/research/d85tsd/asthma Related Topics: Asthma Drugs
CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716